<DOC>
	<DOCNO>NCT01718691</DOCNO>
	<brief_summary>The purpose study assess efficacy safety SyB L-0501 ( two-day consecutive 90 mg/m2/day IV drip infusion ) combination rituximab ( 375 mg/m2 IV drip infusion ) untreated , low-grade B cell non-Hodgkin 's lymphoma mantle cell lymphoma hematopoietic stem cell transplantation indicate .</brief_summary>
	<brief_title>Efficacy Safety Study SyB L-0501 Combination With Rituximab Patients With Untreated , Low-grade B Cell Non-Hodgkin 's Lymphoma Mantle Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Patients histopathologically confirm follow cluster differentiation 20 ( CD20 ) positive lowgrade B cell nonHodgkin 's lymphoma mantle cell lymphoma lymph node biopsy evaluable tissue biopsy within 6 month registration WHO Classification Tumors ( fourth edition ) : Small lymphocytic lymphoma Splenic marginal zone Bcell lymphoma Lymphoplasmacytic lymphoma Extranodal marginal zone Bcell lymphoma mucosaassociated lymphoid tissue ( MALT lymphoma ) Nodal marginal zone Bcell lymphoma Follicular lymphoma ( Grade 1 , 2 , 3a ) Mantle cell lymphoma 2 . Patients measurable lesion ( &gt; 1.5 cm major axis CT ) 3 . Patients without medical history 4 . Patients least 1 follow clinical symptom sign ( exclude mantle cell lymphoma ) : Bulky disease measure &gt; 7 cm major axis CT ( exclude spleen ) B symptom 1 . Fever exceed 38.0ºC unknown cause 2 . Night sweat 3 . Weight decrease exceed 10 % within 6 month patient registration Elevated serum LDH beta 2 microglobulin Three regional lymph node &gt; 3 cm major axis CT Symptomatic splenomegaly Intracranial pressure Pleural effusion/ascites retention 5 . Patients expect live least 3 month 6 . Patients age 20 79 year ( time registration ) 7 . Patients whose Eastern Cooperative Oncology Group ( ECOG ) performance status ( P.S . ) 0～2 8 . Patients adequately maintain major organ function ( bone marrow , heart , lung , liver , kidney ) Neutrophil count : le 1,500 /mm3 Platelet count : le 75,000 /mm3 Aspartate aminotransferase ( AST ) [ Glutamic oxaloacetic transaminase ( GOT ) ] : 3 time standard upper limit site Alanine aminotransferase ( ALT ) [ Glutamic pyruvic transaminase ( GPT ) ] : 3 time standard upper limit site Total bilirubin : 1.5 time standard upper limit site Serum creatinine : 1.5 time standard upper limit site Arterial partial pressure oxygen ( PaO2 ) : le 65 mmHg Electrocardiogram show abnormal finding require treatment Echocardiogram leave ventricular ejection fraction ( LVEF ) : le 55 % 9 . Patients whose informed consent obtain person Patients fall one follow criterion exclude 1 . Patients whose transformation confirm histopathologically 2 . Mantle cell lymphoma patient age 65 year younger 3 . Patients administer received transfusion cytokine formulation GCSF ( granulocyte colony stimulate factor ) erythropoietin within 14 day preregistration test 4 . Patients severe active infectious disorder ( receive antibiotic , antifungal , antivirus IV injection ) 5 . Patients serious complication ( hepatic renal failure ) 6 . Patients severe complication cardiac disease ( example : myocardial infarction , ischemic heart disease ) previous history within 2 year patient registration , patient arrhythmia require treatment 7 . Patients serious gastrointestinal condition ( persistent severe nausea/vomiting diarrhea ) 8 . Patients positive hepatitis B surface ( HBs ) antigen , hepatitis C virus ( HCV ) antibody HIV antibody [ HBs hepatitis B core ( HBc ) positive , patient whose hepatitis B virus ( HBV ) DNA test result indicate positive ] 9 . Patients serious bleed tendency [ disseminate intravascular coagulation ( DIC ) ] 10 . Patients suspect symptom indicative central nervous system ( CNS ) involvement 11 . Patients interstitial pneumonitis , pulmonary fibrosis , pulmonary emphysema complication require treatment medical history . 12 . Patients active multiple primary cancer 13 . Patients receive chemotherapy , radiotherapy , antibody therapy antitumor steroid therapy past 14 . Patients complication medical history autoimmune haemolytic anaemia 15 . Patients administer investigative unapproved drug within 3 month patient registration 16 . Patients addiction drug narcotic , alcoholism 17 . Patients previously receive hematopoietic stem cell transplantation 18 . Patients may pregnant , lactate patient 19 . Patients , whether male female , agree use contraception 20 . Patients otherwise judge investigator subinvestigator unsuitable inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>